Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Zeiser, Robert  [Clear All Filters]
2024
Jutzi JS, Delwel R, Zeiser R, Marneth AE. Editorial: Transcriptional and epigenetic regulation in normal and aberrant hematopoiesis. Front Mol Biosci. 2024;11:1388983.
Bernardi C, Charvet C, Zeiser R, Simonetta F. GM-CSF in Allogenic Hematopoietic Stem Cell Transplantation: from Graft-versus-Host Disease to Graft-versus-Tumor effect. Transplant Cell Ther. 2024.
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kröger N, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024.
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, et al. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. Int J Hematol. 2024.
2023
Adams RC, Carter-Cusack D, Llanes GT, Hunter CR, Vinnakota JManoja, Ruitenberg MJ, Vukovic J, Bertolino P, Chand KK, Wixey JA, et al. CSF1R inhibition promotes neuroinflammation and behavioural deficits during graft-versus-host disease in mice. Blood. 2023.
Zhang YWei, Velasco-Hernandez T, Mess J, Lalioti M-E, Romero-Mulero MCarmen, Obier N, Karantzelis N, Rettkowski J, Schönberger K, Karabacz N, et al. GPRC5C Drives Branched-Chain Amino Acid Metabolism in Leukemogenesis. Blood Adv. 2023.
Gherman R-F, Ewald S, Ihorst G, Strüßmann T, Zeiser R, Wäsch R, Bertz H, Stolz D, Duyster J, Finke J, et al. Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning. Eur J Haematol. 2023.
Jovein MMozaffari, Ihorst G, Duque-Afonso J, Wäsch R, Bertz H, Wehr C, Duyster J, Zeiser R, Finke J, Scherer F. Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure. Blood Cancer J. 2023;13(1):179.
Langhammer M, Schöpf J, Jaquet T, Horn K, Angel M, Spohr C, Christen D, Uhl FMaria, Maié T, Jacobi H, et al. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model. Leukemia. 2023.
Sankowski R, Süß P, Benkendorff A, Böttcher C, Fernandez-Zapata C, Chhatbar C, Cahueau J, Monaco G, Gasull ADalmau, Khavaran A, et al. Multiomic spatial landscape of innate immune cells at human central nervous system borders. Nat Med. 2023.
Zeiser R, Bin Chen Y-, Youssef NN, Ayuk F. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2. Br J Haematol. 2023.
Fatoum H, Zeiser R, Hashmi SK. A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease. Blood Rev. 2023:101142.
Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk A-C, Wehr C, Maas-Bauer K, Melchinger W, Haring E, et al. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. Br J Haematol. 2023.
Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, Wagner E, Hauptrock B, Teschner D, et al. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. Front Immunol. 2023;14:1251593.
Bonig H, Verbeek M, Herhaus P, Braitssch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, et al. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease. J Transl Med. 2023;21(1):837.
2022
Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CPinho, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJurado, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022;9(1):e14-e25.
Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, Passlick B, Schumacher A, Lagies S, Frey A, et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2022:215697.
Biavasco F, Zeiser R. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. Int J Hematol. 2022.
Zeiser R, Warnatz K, Rosshart S, Tanriver Y. GVHD, IBD and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunity. Eur J Immunol. 2022.
2021
Penter L, Gohil SHarish, Huang T, Thrash EM, Schmidt D, Li S, Severgnini M, Neuberg D, F Hodi S, Livak KJ, et al. Coevolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv. 2021.
Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, Passlick B, Heitzler A, Lagies S, Frey A, et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2021.
O'Sullivan D, Stanczak MA, Villa M, Uhl FM, Corrado M, Geltink RIKlein, Sanin DE, Apostolova P, Rana N, Edwards-Hicks J, et al. Fever supports CD8 effector T cell responses by promoting mitochondrial translation. Proc Natl Acad Sci U S A. 2021;118(25).
Duque-Afonso J, Ewald S, Ihorst G, Waterhouse M, Strüessmann T, Zeiser R, Wäsch R, Bertz H, Müller-Quernheim J, Duyster J, et al. The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Adv. 2021.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JMoritz, Musso M, Giebel S, Uzay A, Langmuir P, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021;385(3):228-238.
2020
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157-e167.

Pages